HRP20220576T1 - Farmaceutski pripravak za inhibiciju metastaza raka, koji sadrži, kao aktivni sastojak, antitijelo koje se posebno veže na receptor epidermalnog faktora rasta - Google Patents
Farmaceutski pripravak za inhibiciju metastaza raka, koji sadrži, kao aktivni sastojak, antitijelo koje se posebno veže na receptor epidermalnog faktora rasta Download PDFInfo
- Publication number
- HRP20220576T1 HRP20220576T1 HRP20220576TT HRP20220576T HRP20220576T1 HR P20220576 T1 HRP20220576 T1 HR P20220576T1 HR P20220576T T HRP20220576T T HR P20220576TT HR P20220576 T HRP20220576 T HR P20220576T HR P20220576 T1 HRP20220576 T1 HR P20220576T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- amino acid
- heavy chain
- light chain
- chain variable
- Prior art date
Links
- 102000001301 EGF receptor Human genes 0.000 title claims 8
- 108060006698 EGF receptor Proteins 0.000 title claims 8
- 206010027476 Metastases Diseases 0.000 title claims 4
- 239000004480 active ingredient Substances 0.000 title claims 2
- 230000009401 metastasis Effects 0.000 title claims 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 16
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 102000007299 Amphiregulin Human genes 0.000 claims 2
- 108010033760 Amphiregulin Proteins 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 claims 2
- 101800004564 Transforming growth factor alpha Proteins 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 claims 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
- 102000018710 Heparin-binding EGF-like Growth Factor Human genes 0.000 claims 1
- 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 claims 1
- -1 aroma Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 235000003599 food sweetener Nutrition 0.000 claims 1
- 229960002897 heparin Drugs 0.000 claims 1
- 229920000669 heparin Polymers 0.000 claims 1
- 239000003906 humectant Substances 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 239000003765 sweetening agent Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (7)
1. Farmaceutski pripravak za uporabu u postupku liječenja metastaza raka želuca kod subjekta, koji sadrži antitijelo koje se specifično veže na receptor epidermalnog faktora rasta (EGFR) kao aktivnog sastojka, pri čemu antitijelo sadrži:
a) varijabilnu regiju teškog lanca koja sadrži CDR1, CDR2 i CDR3 respektivno predstavljenu aminokiselinskim sekvencama SEQ ID NO: 1, SEQ ID NO: 2 i SEQ ID NO: 3, varijabilnu regiju lakog lanca koja sadrži CDR1, CDR2 i CDR3 respektivno predstavljenu aminokiselinskim sekvencama SEQ ID NO: 4, SEQ ID NO: 5 i SEQ ID NO: 6, konstantnu regiju teškog lanca, i konstantnu regiju lakog lanca; ili
b) varijabilnu regiju teškog lanca koja sadrži CDR1, CDR2 i CDR3 respektivno predstavljenu aminokiselinskim sekvencama SEQ ID NO: 1, SEQ ID NO: 2 i SEQ ID NO: 3, varijabilnu regiju lakog lanca koja sadrži CDR1, CDR2 i CDR3 respektivno predstavljenu aminokiselinskim sekvencama SEQ ID NO: 9, SEQ ID NO: 5 i SEQ ID NO: 6, konstantnu regiju teškog lanca, i konstantnu regiju lakog lanca.
2. Pripravak za uporabu prema zahtjevu 1, naznačen time što antitijelo sadrži:
a) varijabilnu regiju teškog lanca predstavljenu aminokiselinskom sekvencom SEQ ID NO: 7, varijabilnu regiju lakog lanca predstavljenu aminokiselinskom sekvencom SEQ ID NO: 8, konstantnu regiju teškog lanca, i konstantnu regiju lakog lanca; ili
b) varijabilnu regiju teškog lanca predstavljenu aminokiselinskom sekvencom SEQ ID NO: 7, varijabilnu regiju lakog lanca predstavljenu aminokiselinskom sekvencom SEQ ID NO: 10, konstantnu regiju teškog lanca, i konstantnu regiju lakog lanca.
3. Pripravak za uporabu prema zahtjevu 1, naznačen time što metastazu inducira ili potiče EGFR ligand.
4. Pripravak za uporabu prema zahtjevu 3, naznačen time što je EGFR ligand odabran iz skupine koju čine faktor rasta koji se veže na heparin-EFG (HB-EGF), transformirajući faktor rasta-α (TGF-α), amfiregulin (AREG), i njihova kombinacija.
5. Pripravak za uporabu prema zahtjevu 1, naznačen time što pripravak nadalje sadrži bilo koji odabran iz skupine koju čine farmaceutski prihvatljivi nosač, ekscipijens, lubrikant, humektant, zaslađivač, aroma, konzervans i njihova mješavina.
6. Antitijelo koje se specifično veže na receptor epidermalnog faktora rasta (EGFR) za uporabu u postupku liječenja metastaza raka želuca, koji se sastoji od davanja subjektu antitijela koje se specifično veže na EGFR, antitijelo sadrži:
a) varijabilnu regiju teškog lanca koja sadrži CDR1, CDR2 i CDR3 respektivno predstavljenu aminokiselinskim sekvencama SEQ ID NO: 1, SEQ ID NO: 2 i SEQ ID NO: 3, varijabilnu regiju lakog lanca koja sadrži CDR1, CDR2 i CDR3 respektivno predstavljenu aminokiselinskim sekvencama SEQ ID NO: 4, SEQ ID NO: 5 i SEQ ID NO: 6, konstantnu regiju teškog lanca, i konstantnu regiju lakog lanca; ili
b) varijabilnu regiju teškog lanca koja sadrži CDR1, CDR2 i CDR3 respektivno predstavljenu aminokiselinskim sekvencama SEQ ID NO: 1, SEQ ID NO: 2 i SEQ ID NO: 3, varijabilnu regiju lakog lanca koja sadrži CDR1, CDR2 i CDR3 respektivno predstavljenu aminokiselinskim sekvencama SEQ ID NO: 9, SEQ ID NO: 5 i SEQ ID NO: 6, konstantnu regiju teškog lanca, i konstantnu regiju lakog lanca.
7. Antitijelo za uporabu prema zahtjevu 6, naznačeno time što antitijelo sadrži:
a) varijabilnu regiju teškog lanca predstavljenu aminokiselinskom sekvencom SEQ ID NO: 7, varijabilnu regiju lakog lanca predstavljenu aminokiselinskom sekvencom SEQ ID NO: 8, konstantnu regiju teškog lanca, i konstantnu regiju lakog lanca; ili
b) varijabilnu regiju teškog lanca predstavljenu aminokiselinskom sekvencom SEQ ID NO: 7, varijabilnu regiju lakog lanca predstavljenu aminokiselinskom sekvencom SEQ ID NO: 10, konstantnu regiju teškog lanca, i konstantnu regiju lakog lanca.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/KR2016/004418 WO2017188472A1 (ko) | 2016-04-27 | 2016-04-27 | 표피 성장 인자 수용체에 특이적으로 결합하는 항체를 유효성분으로 포함하는 암의 전이 억제용 약학 조성물 |
EP16900546.9A EP3449939B1 (en) | 2016-04-27 | 2016-04-27 | Pharmaceutical composition for inhibiting metastasis of cancer, comprising, as active ingredient, antibody that specifically binds to epidermal growth factor receptor |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20220576T1 true HRP20220576T1 (hr) | 2022-06-10 |
Family
ID=60159801
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20220576TT HRP20220576T1 (hr) | 2016-04-27 | 2016-04-27 | Farmaceutski pripravak za inhibiciju metastaza raka, koji sadrži, kao aktivni sastojak, antitijelo koje se posebno veže na receptor epidermalnog faktora rasta |
Country Status (13)
Country | Link |
---|---|
US (1) | US11198733B2 (hr) |
EP (1) | EP3449939B1 (hr) |
JP (1) | JP6701382B2 (hr) |
KR (1) | KR102128556B1 (hr) |
CN (1) | CN109195627B (hr) |
DK (1) | DK3449939T3 (hr) |
ES (1) | ES2912903T3 (hr) |
HR (1) | HRP20220576T1 (hr) |
HU (1) | HUE058745T2 (hr) |
LT (1) | LT3449939T (hr) |
PL (1) | PL3449939T3 (hr) |
SI (1) | SI3449939T1 (hr) |
WO (1) | WO2017188472A1 (hr) |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7790164B2 (en) | 2006-11-14 | 2010-09-07 | Van Andel Research Institute | Fragments of antibodies to epidermal growth factor receptor and methods of their use |
KR101108642B1 (ko) * | 2009-09-29 | 2012-02-09 | 주식회사 녹십자 | 표피 성장 인자 수용체에 특이적으로 결합하는 항체 |
AU2011248088B2 (en) * | 2010-05-04 | 2015-06-25 | Merrimack Pharmaceuticals, Inc. | Antibodies against epidermal growth factor receptor (EGFR) and uses thereof |
KR20130083090A (ko) * | 2012-01-10 | 2013-07-22 | 강원대학교산학협력단 | 암 세포의 egfr에 특이적으로 결합하는 항체 및 이의 용도 |
NZ630020A (en) | 2012-03-08 | 2016-08-26 | Halozyme Inc | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof |
JP6441792B2 (ja) * | 2012-05-17 | 2018-12-19 | ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. | Egfrに結合する抗原結合蛋白質 |
US20150147309A1 (en) | 2012-06-06 | 2015-05-28 | Fondazione Telethon | Allosteric chaperones and uses thereof |
CA2908819A1 (en) * | 2013-04-22 | 2014-10-30 | Glycotope Gmbh | Anti-cancer treatments with anti-egfr antibodies having a low fucosylation |
-
2016
- 2016-04-27 SI SI201631511T patent/SI3449939T1/sl unknown
- 2016-04-27 HR HRP20220576TT patent/HRP20220576T1/hr unknown
- 2016-04-27 WO PCT/KR2016/004418 patent/WO2017188472A1/ko active Application Filing
- 2016-04-27 LT LTEPPCT/KR2016/004418T patent/LT3449939T/lt unknown
- 2016-04-27 EP EP16900546.9A patent/EP3449939B1/en active Active
- 2016-04-27 CN CN201680086176.0A patent/CN109195627B/zh active Active
- 2016-04-27 JP JP2018556298A patent/JP6701382B2/ja active Active
- 2016-04-27 HU HUE16900546A patent/HUE058745T2/hu unknown
- 2016-04-27 PL PL16900546T patent/PL3449939T3/pl unknown
- 2016-04-27 KR KR1020187031020A patent/KR102128556B1/ko active IP Right Grant
- 2016-04-27 US US16/096,988 patent/US11198733B2/en active Active
- 2016-04-27 DK DK16900546.9T patent/DK3449939T3/da active
- 2016-04-27 ES ES16900546T patent/ES2912903T3/es active Active
Also Published As
Publication number | Publication date |
---|---|
DK3449939T3 (da) | 2022-05-02 |
JP6701382B2 (ja) | 2020-05-27 |
CN109195627A (zh) | 2019-01-11 |
CN109195627B (zh) | 2022-09-09 |
US20190119388A1 (en) | 2019-04-25 |
JP2019514909A (ja) | 2019-06-06 |
ES2912903T3 (es) | 2022-05-30 |
US11198733B2 (en) | 2021-12-14 |
EP3449939A1 (en) | 2019-03-06 |
EP3449939B1 (en) | 2022-03-30 |
WO2017188472A1 (ko) | 2017-11-02 |
KR20180137502A (ko) | 2018-12-27 |
LT3449939T (lt) | 2022-05-25 |
HUE058745T2 (hu) | 2022-09-28 |
EP3449939A4 (en) | 2019-12-18 |
KR102128556B1 (ko) | 2020-06-30 |
PL3449939T3 (pl) | 2022-06-20 |
SI3449939T1 (sl) | 2022-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR111630A1 (es) | ANTICUERPOS ANTI-SIRPa | |
HRP20201595T1 (hr) | Anti-pd-l1 protutijela i njihova uporaba | |
HRP20201975T1 (hr) | Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba | |
MY186351A (en) | Multispecific antibodies | |
HRP20210393T1 (hr) | Anti-tfr antitijela i njihova uporaba u liječenju proliferativnih i upalnih poremećaja | |
HRP20201022T1 (hr) | Potpuno ljudsko antitijelo protiv ljudskog cd137 i njegova uporaba | |
HRP20190749T1 (hr) | Ljudska antitijela na pd-l1 | |
JP2020500538A5 (hr) | ||
HRP20211129T1 (hr) | Nukleinske kiseline koje kodiraju humana antitijela na sialyl-lewis a | |
RU2018147413A (ru) | PD-L1 специфические антитела | |
HRP20201528T1 (hr) | Biparatopikalni polipeptidi koji antagoniziraju wnt signalizaciju u tumorskim stanicama | |
HRP20210113T1 (hr) | Stabilizirani topljivi prefuzijski rsv f protein za upotrebu u profilaksi rsv infekcije | |
FI3484915T3 (fi) | Uusia zikavirusepitooppeihin spesifisesti sitoutuvia vasta-aineita ja niiden käyttöjä | |
HRP20230060T1 (hr) | Antitijela protiv ox40 i njihova primjena | |
HRP20200767T1 (hr) | Humanizirana anti-humana cd19 protutijela i postupci uporabe | |
RU2017120358A (ru) | Анти-il-1-бета антитела и способы их применения | |
JP2019506841A5 (hr) | ||
RU2016129894A (ru) | Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения | |
RU2018140960A (ru) | Композиции, содержащие комбинированный состав на основе антител к pd-l1 и ctla-4 | |
HRP20211280T1 (hr) | Anti-5t4 antitijela i konjugati antitijelo-lijek | |
HRP20220891T1 (hr) | Protutijela, primjene i postupci | |
JP2016094424A5 (hr) | ||
RU2017103679A (ru) | Способ ингибирования внутриклеточного активированного ras с помощью интакного антитела иммуноглобулинового типа, обладающего способностью к проникновению в цитозоль, и его применение | |
HRP20240167T1 (hr) | Formulacije ljudskih anti-rankl protutijela i postupci njihove upotrebe | |
RU2015102069A (ru) | Антитела к биотину и способы их применения |